CD8A and COVID-19: In theory, HLA-E-restricted CD8+ T cells against SARS-CoV-2 can be affordable and easily developed with donations of COVID-19 convalescent allogeneic samples in large quantities, collected and used when needed for serious COVID-19 cases (Caccamo et al., 2020).